Analisi facoltativa del prodotto
Con il tuo consenso utilizziamo analisi limitate e rispettose della privacy per capire quali percorsi di ricerca funzionano. Non usiamo tracker pubblicitari né registrazioni delle sessioni. Puoi modificare questa scelta nelle Preferenze. Leggi la Informativa sulla privacy.
Stryker Corporation's published Hold conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $114.2B | |
|---|---|---|
| P/E (forward) | 16.5x |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $17.11B | $18.45B | $20.50B | $22.60B | $25.12B | +10.1% |
| Gross profit | $10.97B | $11.58B | $13.06B | $14.44B | $16.07B | +10.0% |
| Operating income | $2.58B | $2.84B | $3.89B | $3.69B | $4.89B | +17.3% |
| Net income | $1.99B | $2.36B | $3.17B | $2.99B | $3.25B | +13.0% |
| EPS (diluted) | $5.21 | $6.17 | $8.25 | $7.76 | $8.40 | +12.7% |
| EBITDA | $3.61B | $4.02B | $5.06B | $6.01B | $6.31B | +15.0% |
| R&D | $1.24B | $1.45B | $1.39B | $1.47B | $1.62B | +7.1% |
| SG&A | $6.43B | $6.39B | $7.11B | $7.69B | $8.65B | +7.7% |
Recent company headlines from major financial publishers.
Accelerated hospital capital equipment spending, record Mako robotic placements in hospital and ASC settings, and rapid clearance of Peripheral Vascular backorders drive double-digit earnings compounding and accelerated operating margin expansion ahead of house expectations.
Stryker executes within its guided organic sales growth corridors, transitioning to steady high-single-digit revenue expansion through FY2030 supported by resilient reconstructive procedure volumes and steady operating margin progression.
| Ke ↓ / g → | 2.5% | 2.8% | 3.0% | 3.3% | 3.5% |
|---|---|---|---|---|---|
| 7.6% | $346 | $357 | $368 | $381 | $395 |
| 8.1% | $321 | $329 | $338 | $348 | $359 |
| 8.6% | $299 | $306 | $313 | $321 | $330 |
| 9.1% | $280 | $286 | $292 | $299 | $306 |
| 9.6% | $264 | $269 | $274 | $279 | $285 |
Upcoming earnings date and setup when available.
Il rating riportato dall'edizione di ricerca pubblicata ogni mese. Un rating confronta il prezzo alla data dell'analisi con il valore equo; non indica se la valutazione si è rivelata corretta.
| Anno | gen | feb | mar | apr | mag | giu | lug | ago | set | ott | nov | dic |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |